2
Registered trials
1
Recruiting
2
Unique sponsors
2
Unique IMPs
0
Commercial trials
Drug classes (ATC)
A
Gastroenterology (ATC A)
1
C
Cardiology (ATC C)
1
Mechanism of action (INN-stem analysis)
SGLT2 inhibitor
1 substance
Receptor fusion protein
1 substance
Phase II:
1
Phase IV:
1
Phase II
1 trial-
EndedRigshospitalet AcademicDAPAGLIFLOZIN
Phase IV
1 trial-
RecruitingAmsterdam UMC Stichting AcademicSOTATERCEPT
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Rigshospitalet | Academic | 1 | Phase II | 0 |
| Amsterdam UMC Stichting | Academic | 1 | Phase IV | 1 |
New trials by year
2023
1
2025
1